Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14183MR)

This product GTTS-WQ14183MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ANGPT2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001118887.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285
UniProt ID O15123
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ14183MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12635MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ11610MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MGD-006
GTTS-WQ10450MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ10682MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ874MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-176
GTTS-WQ15021MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ3167MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ3207MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARGX-110
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW